In which order do biomarkers become abnormal in genetic FTD?

Specialists have reported new findings on the sequence of biomarker abnormalities in carriers of mutations causing frontotemporal dementia (FTD).

The results could help identify carriers with prodromal or early-stage disease, and could also be useful in clinical trials investigating early treatment, they said.

Dr Emma van der Ende from the Erasmus University Medical Center in Rotterdam, The Netherlands, presented the data at AAIC 2021. The research team used discriminative event-based modeling (DEBM) of cross-sectional data from the Genetic Frontotemporal dementia Initiative (GENFI), an international cohort, to investigate the sequence of biomarker abnormalities in pre-symptomatic and symptomatic genetic FTD.